Chardan Capital Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “buy” rating restated by research analysts at Chardan Capital in a report released on Thursday, Benzinga reports. They currently have a $115.00 price target on the biotechnology company’s stock. Chardan Capital’s price objective would indicate a potential upside of 97.49% from the stock’s current price.

A number of other equities research analysts have also recently commented on the stock. Royal Bank Of Canada reiterated an “outperform” rating and issued a $100.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 31st. JPMorgan Chase & Co. upped their price objective on shares of Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 17th. Morgan Stanley raised their price objective on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Finally, Leerink Partners raised their price objective on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a research report on Wednesday, June 17th. Eleven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $99.07.

Arrowhead Pharmaceuticals Stock Down 0.2%

Shares of ARWR stock traded down $0.14 on Thursday, hitting $58.23. The stock had a trading volume of 996,499 shares, compared to its average volume of 2,287,187. Arrowhead Pharmaceuticals has a one year low of $36.57 and a one year high of $95.49. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.77. The company has a market cap of $8.20 billion, a PE ratio of -25.88 and a beta of 1.29. The business has a 50 day moving average price of $76.71 and a 200 day moving average price of $75.99.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The company had revenue of $75.25 million for the quarter, compared to analyst estimates of $44.17 million. Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The company’s revenue for the quarter was up 171.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.26) EPS. Research analysts anticipate that Arrowhead Pharmaceuticals will post -3.62 earnings per share for the current fiscal year.

Insider Activity at Arrowhead Pharmaceuticals

In other news, Director Adeoye Olukotun sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the completion of the transaction, the director owned 31,600 shares of the company’s stock, valued at approximately $2,747,936. This trade represents a 5.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Michael Perry sold 11,600 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the completion of the transaction, the director directly owned 111,459 shares of the company’s stock, valued at approximately $9,730,370.70. The trade was a 9.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter worth $1,208,838,000. Baker BROS. Advisors LP lifted its holdings in shares of Arrowhead Pharmaceuticals by 30.2% during the 4th quarter. Baker BROS. Advisors LP now owns 2,175,645 shares of the biotechnology company’s stock worth $144,441,000 after acquiring an additional 504,883 shares during the period. Siren L.L.C. grew its position in Arrowhead Pharmaceuticals by 7.7% in the first quarter. Siren L.L.C. now owns 1,615,476 shares of the biotechnology company’s stock valued at $101,290,000 after acquiring an additional 115,000 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of Arrowhead Pharmaceuticals by 12.2% during the 1st quarter. Janus Henderson Group PLC now owns 1,436,990 shares of the biotechnology company’s stock valued at $90,119,000 after buying an additional 156,544 shares during the last quarter. Finally, Pictet Asset Management Holding SA raised its holdings in Arrowhead Pharmaceuticals by 23.8% in the first quarter. Pictet Asset Management Holding SA now owns 1,273,266 shares of the biotechnology company’s stock valued at $79,612,000 after acquiring an additional 244,530 shares in the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Trending Headlines about Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: ARO-MAPT demonstrated substantial tau reduction. Interim Phase 1/2a data showed reductions of up to 73% in tau, a protein associated with Alzheimer’s disease. Arrowhead said the study provides the first clinical validation of its TRiM platform’s ability to deliver siRNA across the blood-brain barrier and achieve deep, durable gene knockdown in the brain. Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data
• Positive Sentiment: Analysts remain strongly bullish. UBS initiated coverage with a Buy rating and a $109 price target. Chardan Capital reaffirmed Buy with a $115 target, while HC Wainwright maintained Buy with a $120 target. These targets imply approximately 86% to 105% upside from recent levels and suggest analysts view the Alzheimer’s program and broader RNAi pipeline as significant value drivers.
• Positive Sentiment: Coverage of ARO-MAPT emphasized the potential of Arrowhead’s TRiM CNS delivery platform, which could support additional treatments for Alzheimer’s and other tauopathies if the technology continues to show clinical benefit. Arrowhead discusses ARO-MAPT interim results and TRiM CNS delivery
• Neutral Sentiment: The results are preliminary and were generated in healthy volunteers rather than Alzheimer’s patients. The program remains investigational, so future patient efficacy, safety, regulatory, and commercialization risks remain substantial. Arrowhead reports positive Phase 1/2a data for ARO-MAPT

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. Its research is based primarily on RNA interference (RNAi), a biological process that reduces the production of specific proteins by targeting messenger RNA before it can be used to make those proteins.

The company uses its proprietary Targeted RNAi Molecule (TRiM) platform to design and deliver RNAi therapeutics to selected tissues, including the liver and lungs.